The company was set up in March 1998. In July 2001, the company's products Saxobin (Doxazosinmesylate) tablets2mg was agreed for future reference by the Department of Health. Ref: DOH drug No. 0900039817. In October 2001, the company's products anti-osteoporosis drugs SO101C received grants the leading new product development from Industrial Development Bureau Ministry of Economic Affairs. In March 2002, the company products dementia long-term treatment of percutaneous absorption patch SA201D was patented by U.S. Patent numbers: US6352715B103/05/02. In April 2002, the company MG103 R & D results were published in Journal of Cellular Biochemistry 84 : 532-544 (2002 ). In August 2002, its shares went though public offering. In September 2002, anti-osteoporosis medicine SO101C was approved by Department of Health and granted formal entry into Phase II human clinical trials.
Headquarters
10F-6, No.3,Yuanqu St., Nangang District
Taipei City; Taipei City;
Contact Details: Purchase the Sagittarius Life Science Corp. report to view the information.
Website: http://www.naturalbiokey.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service